ALX Oncology (ALXO)

Executive Summary

ALX Oncology is a clinical-stage biopharmaceutical company advancing evorpacept, a next-generation CD47 blocker designed to enhance the efficacy of antibody-based cancer therapies while minimizing toxicity. The company's lead program combines evorpacept with multiple agents (e.g., trastuzumab, pembrolizumab) across solid and hematologic malignancies. ALX Oncology is also developing ALX2004, a novel antibody-drug conjugate targeting PTK7, currently in Phase 1 for NSCLC and other solid tumors. With a focused pipeline and a strategy to establish evorpacept as a cornerstone combination therapy, the company aims to address significant unmet needs in oncology. ALX Oncology's clinical data has shown promising safety and efficacy signals, particularly in combination with standard-of-care regimens. The ongoing Phase 1/2 trial in metastatic breast cancer and the Phase 1 ALX2004 trial represent key near-term value drivers. Despite competition in the CD47 space, evorpacept's differentiated safety profile and broad combinability position it favorably. The company's modest valuation (~$239M) reflects early-stage risk but also upside potential from upcoming data readouts. Key catalysts include initial efficacy data from the Phase 1/2 breast cancer trial and dose-escalation results from the ALX2004 study, both expected in 2026. Successful execution could lead to partnership opportunities and accelerated development.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data for evorpacept + trastuzumab in metastatic breast cancer50% success
• Q2 2027Phase 1 dose-escalation data for ALX2004 in advanced solid tumors40% success